Targacept (NASDAQ:TRGT), already in the midst of a corporate restructuring, must now also search for a new CEO. Don deBethizy is resigning from his positions as CEO and chairman of the drug development company. In a statement, deBethizy said he “decided to step down for personal considerations.” But the move follows some setbacks for the […]
Targacept’s (NASDAQ:TRGT) drug development effort is focused on the here, now and soon to be future. It has to be because a corporate restructuring that will lead to layoffs of 65 workers — nearly half of Targacept employees — has had particular impact on the company’s preclinical research. That means Targacept will need to […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Targacept‘s (NASDAQ:TRGT) first quarter dealt the company several blows with a phase 3 clinical trial failure for its lead drug candidate and a missed target in another clinical program. Failure of depression candidate TC-5214 led to the formal termination of the company’s partnership with AstraZeneca (NYSE:AZN) on that compound. Rights to TC-5214 revert to Targacept […]
Targacept (NASDAQ:TRGT) is slashing its workforce by nearly half, part of a restructuring plan that comes one month after its lead drug candidate, a depression drug, failed the last of a series of phase 3 clinical trials. The company is laying off 65 employees, approximately 46 percent of its staff. Also departing the company will […]
The asthma treatment Targacept (NASDAQ:TRGT) is developing actually did not perform as well in clinical trials as initially thought. Targacept last month released top-line phase 2 results for TC-6987 that showed the asthma compound met both goals in the clinical trial. But the Winston-Salem, North Carolina drug developer has revised its top-line results and said […]
A Targacept (NASDAQ:TRGT) compound developed for potential applications in asthma and type 2 diabetes has mixed mid-stage clinical trial results that show success in asthma but failure in diabetes. As a result, Targacept will no longer pursue TC-6987 in the diabetes indication. The mixed results come a week after the Winston-Salem, North Carolina company reported […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Depression treatment TC-5214 remains Targacept‘s (NASDAQ:TRGT) lead drug candidate and perhaps it was with that in mind that CEO Don DeBethizy started the earnings conference call with an update on that drug program. But there was nothing new for the company to report on TC-5214 since disclosing in December the failure of the compound in […]
Targacept (NASDAQ:TRGT) has seen two phase 3 clinical trial failures in the last two months for its depression drug candidate. Now the company has some better news, albeit for a different indication. Drug partner AstraZeneca (NYSE:AZN) will take on a Targacept Alzheimer’s disease drug candidate for further clinical studies. AstraZeneca will conduct and fund phase […]
The depression treatment that Targacept (NASDAQ:TRGT) has identified as its lead drug candidate has failed in a phase 3 clinical trial, the second failure in less than two months for the compound. Put simply, the drug candidate TC-5214 was no better than a placebo in the late-stage trial. If Targacept is to see success for […]
Drug development company Targacept (NASDAQ:TRGT) has started two mid-stage clinical trials on a compound that could have applications in schizophrenia as well as attention deficit-hyperactivity disorder. It’s the second round of phase 2 trials for the compound from Winston-Salem, North Carolina-based Targacept. Earlier this year, TC-5619 showed positive results in a phase 2 trial that […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Targacept (NASDAQ:TRGT) remains committed to moving forward with three more phase 3 clinical trials attempting to develop depression’s first new treatment mechanism in decades despite results of one trial showing that the compound partnered with AstraZeneca (NYSE:AZN) performed no better than a placebo. CEO Don deBethizy said he could not explain why TC-5214 did not […]
When Targacept (NASDAQ:TRGT) and AstraZeneca (NYSE:AZN) changed their collaboration agreement in 2007 by adding a new compound being studied in cognitive disorders, the addition was done as an option deal. Winston-Salem, North Carolina-based Targacept got $2 million up front. If TC-5619 achieved clinical proof of concept, AstraZeneca had the option to pay $40 million for […]
A Targacept (NASDAQ:TRGT) compound that has been studied in a range of cognitive disorders with drug partner AstraZeneca (NYSE:AZN) has started in mid-stage clinical studies as a potential new Alzheimer’s disease treatment. Winston-Salem, North Carolina-based Targacept is studying AZD3480 in patients with mild to moderate Alzheimer’s disease. The study is part of a special protocol […]
Targacept (NASDAQ:TRGT) has $10 million in additional funds to apply toward clinical trials on a drug candidate intended for patients with schizophrenia. The Winston-Salem, North Carolina biopharmaceutical company last month completed a stock offering that net the company just over $70 million. On Friday, Targacept announced it has completed the sale of an additional 548,780 […]
Now that AstraZeneca (NYSE:AZN) has determined it won’t license Targacept‘s compound for schizophrenia, the drug development company is preparing to raise up to $75 million to develop the drug candidate on its own. Winston-Salem, North Carolina-based Targacept (NASDAQ:TRGT) set the dollar target in a preliminary prospectus filed Tuesday with the U.S. Securities and Exchange Commission. […]